{
  "totalSections": 101,
  "sectionsByLevel": {
    "level1": 34,
    "level2": 62,
    "level3": 3,
    "level4": 2
  },
  "sectionsBySource": {
    "pattern": 98,
    "preNumbered": 2,
    "tableOfContents": 1,
    "content": 0
  },
  "sections": [
    {
      "index": 0,
      "title": "Clinical Protocol",
      "level": 1,
      "source": "pre-numbered",
      "patternType": "document-header",
      "number": "N/A",
      "contentPreview": "Title: A Multicenter, Randomized, Placebo - Controlled, Double-Blind, Phase 3 Trial of Single -Dose Intravesical EOquin as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer Protocol Number: SPI-611 IND Numbe...",
      "contentLength": 1240,
      "originalLine": "N/A"
    },
    {
      "index": 1,
      "title": "TABLE OF CONTENTS",
      "level": 1,
      "source": "pre-numbered",
      "patternType": "document-header",
      "number": "N/A",
      "contentPreview": "Section Page 1. LIST OF ABBREVIATION S ..............................................................................................5 2. SYNOPSIS ...........................................................................................................................6 3. BACKGROUND .................",
      "contentLength": 13429,
      "originalLine": "N/A"
    },
    {
      "index": 2,
      "title": "TABLE OF CONTENTS",
      "level": 1,
      "source": "table-of-contents",
      "patternType": "toc",
      "number": "N/A",
      "contentPreview": "TABLE OF CONTENTS Section Page 1. LIST OF ABBREVIATION S ..............................................................................................5 2. SYNOPSIS ...........................................................................................................................6 3. BACKGRO...",
      "contentLength": 13447,
      "originalLine": "TABLE OF CONTENTS"
    },
    {
      "index": 3,
      "title": "LIST OF ABBREVIATION S",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "1",
      "contentPreview": "AE adverse event ALT amino alanine transferase AST aspartate aminotransferase BUN blood urea nitrogen CBC complete blood count CFR Code of Federal Regulations CR complete response CIS Carcinoma in situ CRF case report form CRA Clinical Research Associate CTCAE Common Toxicity Criteria Adverse Events...",
      "contentLength": 952,
      "originalLine": "1. LIST OF ABBREVIATION S"
    },
    {
      "index": 4,
      "title": "SYNOPSIS",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "2",
      "contentPreview": "Title A Multicenter, Randomized, Placebo -Controlled, Double -Blind Phase 3 Trial of Single -Dose Intravesical EOquin as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer Phase This is a Phase 3 Clinical Stu...",
      "contentLength": 3062,
      "originalLine": "2. SYNOPSIS"
    },
    {
      "index": 5,
      "title": "BACKGROUND",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "3",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "3. BACKGROUND"
    },
    {
      "index": 6,
      "title": "Noninvasive Bladder Cancer",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "3.1",
      "contentPreview": "Bladder cancer is the seventh most common cancer worldwide, accounting for approximately 280,000 new cases in the EU and over 60,000 new cases in the US. Bladder cancer ranks as the fourth most common malignancy in men and the tenth most common neoplasm in women. In the United States, over 13,000 de...",
      "contentLength": 4865,
      "originalLine": "3.1 Noninvasive Bladder Cancer"
    },
    {
      "index": 7,
      "title": "EOquin",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "3.2",
      "contentPreview": "EOquin (apaziquone for intravesical instillation) is a bioreductive alkylating indoloquinone that needs to be enzymatically activated in vivo in order to cause cell death. Both its patt ern of activation and its activity in tumor cell lines exhibit marked differences from mitomycin C, the prototype...",
      "contentLength": 592,
      "originalLine": "3.2 EOquin"
    },
    {
      "index": 8,
      "title": "Preclinical and Clinical Studies with EOquin  of diluent are to be used for each vial of EOquin.",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "3.3",
      "contentPreview": "3.3.1 In vitro assays with panels of tumor lines showed a preferential cytotoxicity of EOquin in most solid tumors as opposed to leukemia lines. The drug appeared significantly more potent than mitomycin C. Preclinical Studies In intravenous and intraperitoneal toxicology studies, the drug was safe...",
      "contentLength": 436,
      "originalLine": "3.3 Preclinical and Clinical Studies with EOquin  of diluent are to be used for each vial of EOquin."
    },
    {
      "index": 9,
      "title": "Clinical Studies with EOquin",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "3.4",
      "contentPreview": "3.4.1 There have been three studies of EOquin administered by the intravesical route. Intravesical Studies The first study was an intrapatient dose escalation study performed in patients with recurrent superficial (Ta-T1, G1-G2) bladder cancer in which all but one “marker” lesion had been removed a...",
      "contentLength": 4364,
      "originalLine": "3.4 Clinical Studies with EOquin"
    },
    {
      "index": 10,
      "title": "Summary of Risks and Benefits",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "3.5",
      "contentPreview": "3.5.1 EOquin is an investigational product, and its safety profile has not been firmly established. In studies performed t o date, it appears to be well tolerated with most side effects limited to the bladder. Potential Risks The physician is urged to use clinical judgment regarding the appropriate...",
      "contentLength": 1297,
      "originalLine": "3.5 Summary of Risks and Benefits"
    },
    {
      "index": 11,
      "title": "Justification of the Dose, Schedule and Route of Administration of EOquin",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "3.6",
      "contentPreview": "As noted above in section 3.1, single instillations of drugs such as mitomycin C and epirubicin have been shown to reduce recurrences of superficial bladder cancers when administered in the immediate post-TUR period. The sooner the drug can be instilled, the better, but for practical purposes, most ...",
      "contentLength": 646,
      "originalLine": "3.6 Justification of the Dose, Schedule and Route of Administration of EOquin"
    },
    {
      "index": 12,
      "title": "Population to be Studied",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "3.7",
      "contentPreview": "This study will enroll approximately 800 adult patients with noninvasive bladder cancer. Eligible patients will have 4 or fewer tumors, none of which exceeds 3.5 cm in diameter....",
      "contentLength": 177,
      "originalLine": "3.7 Population to be Studied"
    },
    {
      "index": 13,
      "title": "OBJECTIVE",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "4",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "4. OBJECTIVE"
    },
    {
      "index": 14,
      "title": "Primary Objective",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "4.1",
      "contentPreview": "To evaluate the recurrence rate of bladder cancer at 2 years in randomized patients with tumor histology Ta, G1-G2 who receive TUR-BT plus EOquin versus those who receive TUR -BT plus placebo....",
      "contentLength": 192,
      "originalLine": "4.1 Primary Objective"
    },
    {
      "index": 15,
      "title": "Secondary Objective",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "4.2",
      "contentPreview": "• To evaluate time to first recurrence in patients with tumor histology Ta, G1 -G2 who receive TUR -BT plus EOquin versus those who receive TUR-BT plus placebo. • To evaluate progression to higher stage or grade, number of recurrences per patient, disease free interval, disease free survival and ov...",
      "contentLength": 500,
      "originalLine": "4.2 Secondary Objective"
    },
    {
      "index": 16,
      "title": "STUDY DESIGN",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "5",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "5. STUDY DESIGN"
    },
    {
      "index": 17,
      "title": "Overview",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "5.1",
      "contentPreview": "This is a multi-center, randomized, double- blind, placebo- controlled trial. All patients must sign a consent form prior to undertaking any study- related procedures. Screening procedures must be performed prior to and within 14 days of randomization. After screening procedures are performed, appro...",
      "contentLength": 1478,
      "originalLine": "5.1 Overview"
    },
    {
      "index": 18,
      "title": "Dose, Route of Administrati on and Schedule of Study Drug",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "5.2",
      "contentPreview": "5.2.1 Randomized patients will receive either matching Placebo or EOquin  4 mg reconstituted with 40 mL of diluent. The 40 mL of reconstituted study drug is to be instilled into the bladder via an indwelling, Foley catheter, where it is to be retained for 60 minutes. For details of study drug prepa...",
      "contentLength": 503,
      "originalLine": "5.2 Dose, Route of Administrati on and Schedule of Study Drug"
    },
    {
      "index": 19,
      "title": "Study Duration and Follow- up",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "5.3",
      "contentPreview": "All patients will be followed for two years....",
      "contentLength": 44,
      "originalLine": "5.3 Study Duration and Follow- up"
    },
    {
      "index": 20,
      "title": "Enrollment",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "5.4",
      "contentPreview": "Patients who meet all of the inclusion criteria and none of the exclusion criteria may be considered for randomization. Following confirmation of the number and size of the bladder tumors at TUR, the patient will be randomized to receive either placebo or EOquin....",
      "contentLength": 264,
      "originalLine": "5.4 Enrollment"
    },
    {
      "index": 21,
      "title": "Blinding Procedures",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "5.5",
      "contentPreview": "This is a randomized, double blind, placebo-controlled study. An independent central pathology laboratory blinded to the treatment assignments will perform the histologic eligibility and histologic outcome assessments....",
      "contentLength": 218,
      "originalLine": "5.5 Blinding Procedures"
    },
    {
      "index": 22,
      "title": "Termination of the Study",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "5.6",
      "contentPreview": "The study will continue until all randomized patients have completed 2 years of follow up. The Sponsor retains the right to terminate the study at any time....",
      "contentLength": 156,
      "originalLine": "5.6 Termination of the Study"
    },
    {
      "index": 23,
      "title": "PATIENT SELECTION AN D WITHDRAWAL",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "6",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "6. PATIENT SELECTION AN D WITHDRAWAL"
    },
    {
      "index": 24,
      "title": "Inclusion Criteria",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "6.1",
      "contentPreview": "All of the following questions must be answered “Yes” in order for the patient to participate in the study. 1. Has the patient given written informed consent? 2. Is the patient at leas t 18 years old? 3. Does the patient have transitional cell carcinoma of the bladder with clinically apparent stage ...",
      "contentLength": 623,
      "originalLine": "6.1 Inclusion Criteria"
    },
    {
      "index": 25,
      "title": "Exclusion Criteria",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "6.2",
      "contentPreview": "All of the following questions must be answered “No” in order for the patient to participate in the study. 1. Does the patient have more than 4 bladder tumors? 2. Does any single bladder tumor exceed 3.5 cm in diameter? 3. Does the patient have a single, primary (no previous diagnosis of TCC) bladde...",
      "contentLength": 316,
      "originalLine": "6.2 Exclusion Criteria"
    },
    {
      "index": 26,
      "title": "Has the patient ever received EOquin",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "4",
      "contentPreview": "?...",
      "contentLength": 2,
      "originalLine": "4. Has the patient ever received EOquin"
    },
    {
      "index": 27,
      "title": "Does the patient have, or has the patient ever had, any bladder tumor known to be",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "5",
      "contentPreview": "other than stage Ta or grade G1 or G2 (low grade [WHO/ISUP classification])?...",
      "contentLength": 76,
      "originalLine": "5. Does the patient have, or has the patient ever had, any bladder tumor known to be"
    },
    {
      "index": 28,
      "title": "Does the patient have, or has the patient ever had any bladder tumor with",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "6",
      "contentPreview": "histology other than transitional cell carcinoma? 7. Does the patient have, or has the patient ever had, CIS? 8. Does the patient have an active urinary tract infection? 9. Does the patient have a bleeding disorder or a screening platelet count < 100 x 10 9/L? 10. Does the patient have any unstable ...",
      "contentLength": 967,
      "originalLine": "6. Does the patient have, or has the patient ever had any bladder tumor with"
    },
    {
      "index": 29,
      "title": "Patient Withdrawal from Treatment",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "6.3",
      "contentPreview": "Since this is a single dose study, the only way to withdraw from treatment is to shorten the period of time during which the study drug is retained in the bladder. If during the retention a patient suffers a severe adverse experience that, in the judgment of the Principal Investigator or the Medical...",
      "contentLength": 496,
      "originalLine": "6.3 Patient Withdrawal from Treatment"
    },
    {
      "index": 30,
      "title": "Patient Withdrawal from Study",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "6.4",
      "contentPreview": "Following the single dose of study drug, patients may be discontinued from the study for any of the following reasons: 1. The patient withdraws consent. 2. The patient refuses follow-up cystoscopy. 3. The patient is lost to follow -up. 4. Investigator’s or Sponsor’s decision...",
      "contentLength": 275,
      "originalLine": "6.4 Patient Withdrawal from Study"
    },
    {
      "index": 31,
      "title": "STUDY VISIT PROCEDURES",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "7",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "7. STUDY VISIT PROCEDURES"
    },
    {
      "index": 32,
      "title": "Screening Iden tification Number",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "7.1",
      "contentPreview": "Patients will be assigned a screening identification number (screening numbers) for screening purposes. Screening numbers will be assigned by the site after a patient has signed the Informed Consent Document. The screening ID number wil l be site’s three - digit ID number, followed by three unique d...",
      "contentLength": 519,
      "originalLine": "7.1 Screening Iden tification Number"
    },
    {
      "index": 33,
      "title": "Screening and Pre -Study Assessments",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "7.2",
      "contentPreview": "Prior to the performance of any protocol-specific procedures, written informed consent must be obtained. The following assessments should be performed in order to determine whether the patien t is eligible for this study. All screening procedures must be performed prior to and within 14 days of rand...",
      "contentLength": 879,
      "originalLine": "7.2 Screening and Pre -Study Assessments"
    },
    {
      "index": 34,
      "title": "Randomization",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "7.3",
      "contentPreview": "Patients will be randomized 1:1 to either EOquin  or placebo. The randomization plan will use a permuted block design and will not be stratified by prognostic factors. However, patients will be randomized within center with a block size of four. Patient numbers will be assigned sequentially at each...",
      "contentLength": 1137,
      "originalLine": "7.3 Randomization"
    },
    {
      "index": 35,
      "title": "On-Study Procedures and Evaluations",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "7.4",
      "contentPreview": "The following tests will be conducted according to the Schedule of Events (See Section 19 and 20). 7.4.1 Brief physical examination includes auscultation of the heart and lungs, and examination of the abdomen. Examination of other systems, including rectal and pelvic examination, should be performed...",
      "contentLength": 652,
      "originalLine": "7.4 On-Study Procedures and Evaluations"
    },
    {
      "index": 36,
      "title": "CBC with  differential and platelet count, chemistry panel (including electrolytes, BUN,",
      "level": 3,
      "source": "pattern",
      "patternType": "numbered-subsub",
      "number": "7.4.3",
      "contentPreview": "creatinine, total bilirubin, alkaline phosphatase, LDH, ALT and AST), and urinalysis will be performed as indicated on the Schedule of Events ( Section 19 and 20) . Urine cytolo gy will be performed at screening and at 6 -month intervals during follow up. Laboratory Evaluations Urinalysis will be pe...",
      "contentLength": 2356,
      "originalLine": "7.4.3 CBC with  differential and platelet count, chemistry panel (including electrolytes, BUN,"
    },
    {
      "index": 37,
      "title": "Ta, G1- G2 patients  Cystoscopy",
      "level": 4,
      "source": "pattern",
      "patternType": "numbered-detail",
      "number": "7.4.8.1",
      "contentPreview": "Cystoscopy will be performed every three months ± 10 days, from the date of the TUR- BT through year two. An operative report should contain the number, size and location of the recurrent tumors, if any. Suspicious lesions should be biopsied, and recurrences reported on the appropriate CRF. All hist...",
      "contentLength": 702,
      "originalLine": "7.4.8.1  Ta, G1- G2 patients  Cystoscopy"
    },
    {
      "index": 38,
      "title": "Higher grade/stage patients",
      "level": 4,
      "source": "pattern",
      "patternType": "numbered-detail",
      "number": "7.4.8.2",
      "contentPreview": "Cystoscopy will be performed every three months ± 20 days, from the date of the start of the additional therapy through year two. Suspicious lesions should be biopsied, and recurrences reported on the appropriate CRF. An operative report should contain the number, size and location of the recurrent ...",
      "contentLength": 1767,
      "originalLine": "7.4.8.2  Higher grade/stage patients"
    },
    {
      "index": 39,
      "title": "Follow- up of Recurrent Disease",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "7.5",
      "contentPreview": "On any surveillance cystoscopy, if the patient is found to have a recurrence with histology other than Ta, G1-G2 and requires additional therapy, the follow-up surveillance cystoscopy window is 3 months ± 20 days from the start of the additional therapy....",
      "contentLength": 254,
      "originalLine": "7.5 Follow- up of Recurrent Disease"
    },
    {
      "index": 40,
      "title": "STUDY DRUG",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "8",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "8. STUDY DRUG"
    },
    {
      "index": 41,
      "title": "Composition of EOquin",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.1",
      "contentPreview": "EOquin (apaziquone for intravesical instillation) is a sterile, non -pyrogenic, lyophilized product supplied in clear glass vials. It contains 4 mg apaziquone, mannitol and sodium bicarbonate. After reconstitution, EOquin has a reddish appearance similar to that of cranberry juice....",
      "contentLength": 284,
      "originalLine": "8.1 Composition of EOquin"
    },
    {
      "index": 42,
      "title": "Composition of Matching Placebo",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.2",
      "contentPreview": "Matching placebo containing FD&C red dye #40, sodium chloride and ma nnitol is supplied in identical appearing vials. Reconstitution and instillation procedures for placebo are the same as for EOquin ....",
      "contentLength": 202,
      "originalLine": "8.2 Composition of Matching Placebo"
    },
    {
      "index": 43,
      "title": "Composition of Diluent",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.3",
      "contentPreview": "8.3.1 The diluent for EOquin contains a solution of sodium bicarbonate, propylene glycol and disodium EDTA in sterile water Diluent for EOquin 8.3.2 The diluent for placebo contains 9 mg/mL sodium chloride Diluent for Placebo...",
      "contentLength": 226,
      "originalLine": "8.3 Composition of Diluent"
    },
    {
      "index": 44,
      "title": "Dose of Study Drug",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.4",
      "contentPreview": "4mg of EOquin in 40 mL of diluent will be administered intravesically via an indwelling Foley catheter and retained for o ne hour....",
      "contentLength": 130,
      "originalLine": "8.4 Dose of Study Drug"
    },
    {
      "index": 45,
      "title": "Shipping of the Study Drug",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.5",
      "contentPreview": "Study drug is shipped on cool packs in insulated containers....",
      "contentLength": 60,
      "originalLine": "8.5 Shipping of the Study Drug"
    },
    {
      "index": 46,
      "title": "Storage of Study Drug",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.6",
      "contentPreview": "Study drug kits are to be refrigerated (approximately 2 -8°C) in a secure area. Study drug should be protected from direct light. Becau se patient specific supplies will be provided to sites, diluent and sterile water for injection will be stored with the study drug in the refrigerator at approximat...",
      "contentLength": 311,
      "originalLine": "8.6 Storage of Study Drug"
    },
    {
      "index": 47,
      "title": "Supply and labeling of Study Drug and Diluent",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.7",
      "contentPreview": "8.7.1 Study drug will be provided by the Sponsor as patient specific boxes containing study drug, 2 ampoules of diluent (10 mL each) and a 20 mL vial of sterile water for injection. Each box will be labeled (white label) with the patient’s randomization numb er. Each vial of the study drug will be l...",
      "contentLength": 3038,
      "originalLine": "8.7 Supply and labeling of Study Drug and Diluent"
    },
    {
      "index": 48,
      "title": "Preparation of Study Drug for Randomization Numbers: 1001 -",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.8",
      "contentPreview": "Equipment needed: one vial of study drug, two 10 mL ampoules of Diluent, sterile water for injection, one 50 or 60 mL Luer-lok syringe, catheter tip adapter, 18 gauge needle, protective clothing. Study drug for instillation should be prepared on the day of surgery after the patient’s TUR . The prepa...",
      "contentLength": 1334,
      "originalLine": "8.8 Preparation of Study Drug for Randomization Numbers: 1001 - 1336"
    },
    {
      "index": 49,
      "title": "Preparation of Study Drug for Randomization Numbers 1337 – 1900 & 4501-",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.9",
      "contentPreview": "4580 Equipment needed: one vial of study drug, one vial of diluent containing 45 mL of diluent, one 50 or 60 mL Luer-lok syringe, catheter tip adapter (supplied), 18 gauge needle, protective clothing. Study drug for instillation should be prepared on the day of surgery after the patient’s TUR . The ...",
      "contentLength": 362,
      "originalLine": "8.9 Preparation of Study Drug for Randomization Numbers 1337 – 1900 & 4501-"
    },
    {
      "index": 50,
      "title": "Wear protective clothing",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "1",
      "contentPreview": "2. Draw up 40 mL of diluent in the syringe (approximately 5 mL will remain in the vial) 3. Inject ap proximately 5 -10 mL of diluent into the study drug vial 4. Gently agitate the vial and attached syringe until no undissolved particles are visible (Do not detach the syringe and the study drug vial)...",
      "contentLength": 300,
      "originalLine": "1. Wear protective clothing"
    },
    {
      "index": 51,
      "title": "Withdraw all dissolved study drug into the syringe",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "5",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "5. Withdraw all dissolved study drug into the syringe"
    },
    {
      "index": 52,
      "title": "Withdraw the syringe from the study drug vial",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "6",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "6. Withdraw the syringe from the study drug vial"
    },
    {
      "index": 53,
      "title": "Cover the needle with needle cover",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "7",
      "contentPreview": "8. Invert the syringe at least 10 times to ensure adequate mixing...",
      "contentLength": 65,
      "originalLine": "7. Cover the needle with needle cover"
    },
    {
      "index": 54,
      "title": "Carefully expel all trapped air in the syringe",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "9",
      "contentPreview": "10. The final volume in the syringe should be 40 mL Reconstituted study drug is stable at room temperature for up to eight hours. If the reconstituted product is not used within eight hours, it should be discarded....",
      "contentLength": 214,
      "originalLine": "9. Carefully expel all trapped air in the syringe"
    },
    {
      "index": 55,
      "title": "Criteria for Mixing Study Drug",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.10",
      "contentPreview": "If study drug is reconstituted and not used it may be difficult to resupply the used ki t in a reasonable time. Therefore patient eligibility should be confirmed prior to drug reconstitution. Please make sure that all of the following criteria are met prior to drug reconstitution: • Patient has no m...",
      "contentLength": 491,
      "originalLine": "8.10 Criteria for Mixing Study Drug"
    },
    {
      "index": 56,
      "title": "Administration of Study Drug",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.11",
      "contentPreview": "Study drug is to be instilled into the bladder via an indwelling Foley catheter within 6 hours of TUR-BT. For this purpose, a catheter tip adapter has been supplied. Remove the 18- gauge needle from the syringe and attach the adapter. After hemostasis is obtained, the bladder should be emptied and t...",
      "contentLength": 502,
      "originalLine": "8.11 Administration of Study Drug"
    },
    {
      "index": 57,
      "title": "Disposal of Study Drug",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.12",
      "contentPreview": "At the end of the 60-minute period of retention, study drug should be carefully drained into a suitable container and disposed of according to the institution’s policies for disposal of hazardous waste....",
      "contentLength": 202,
      "originalLine": "8.12 Disposal of Study Drug"
    },
    {
      "index": 58,
      "title": "Product Accountability",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "8.13",
      "contentPreview": "The Investigator and the investigational pharmacist must maintain accurate accounting of investiga tional product. During the study, the following information must be recorded: • Date of receipt, quantity and identification of the product received from the Sponsor • ID number of the patient to whom ...",
      "contentLength": 1191,
      "originalLine": "8.13  Product Accountability"
    },
    {
      "index": 59,
      "title": "COMCOMITANT AND PROHIBITED MEDICATIONS",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "9",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "9. COMCOMITANT AND PROHIBITED MEDICATIONS"
    },
    {
      "index": 60,
      "title": "Concomitant Medications",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "9.1",
      "contentPreview": "For all patients, subsequent intravesical therapies (chemo and immunotherapy) will be recorded. Patients may use non -prescription analgesics or antipyretics to manage side effects associated with TUR -BT and administration of study drug. The Investigator may also prescribe standard postoperative me...",
      "contentLength": 310,
      "originalLine": "9.1 Concomitant Medications"
    },
    {
      "index": 61,
      "title": "Prohibited Medications",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "9.2",
      "contentPreview": "Prior to recurrence, patients with tumor histology of Ta, G1-G2 may not receive other medications to treat bladder cancer....",
      "contentLength": 122,
      "originalLine": "9.2 Prohibited Medications"
    },
    {
      "index": 62,
      "title": "EFFICACY ASSESSMENTS",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "10",
      "contentPreview": "The primary efficacy assessment will be the recurrence rate at 2 years in patients with Ta, G1-G2 histology receiving one immediate instillation of EOquin or placebo following TURBT. These patients will be assessed cystoscopically at three-month intervals calculated from the time of randomization. ...",
      "contentLength": 898,
      "originalLine": "10. EFFICACY ASSESSMENTS"
    },
    {
      "index": 63,
      "title": "SAFETY ASSESSMENTS",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "11",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "11. SAFETY ASSESSMENTS"
    },
    {
      "index": 64,
      "title": "Definitions",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "11.1",
      "contentPreview": "11.1.1 An Definition: Adverse Event adverse event...",
      "contentLength": 49,
      "originalLine": "11.1 Definitions"
    },
    {
      "index": 65,
      "title": "(AE) is any unfavorable and unintended sign, symptom, or disease",
      "level": 3,
      "source": "pattern",
      "patternType": "numbered-subsub",
      "number": "11.1.2",
      "contentPreview": "experienced by a study participant while in a clinical study, whether or not considered related to the investigational product. Examples include: reactions or side effects, a pre- existing condition that worsens in severity or frequency, a concurrent illness, an injury, or a clinically significant l...",
      "contentLength": 3026,
      "originalLine": "11.1.2  (AE) is any unfavorable and unintended sign, symptom, or disease"
    },
    {
      "index": 66,
      "title": "to the investigational product.",
      "level": 3,
      "source": "pattern",
      "patternType": "numbered-subsub",
      "number": "11.1.4",
      "contentPreview": "The severity of an AE should be defined according to the National Cancer Institute (NCI) Common Toxicity Criteria Adverse Events (CTC AE) Version 3.0 which will be provided to the sites. AEs that are not listed in the NCI Common Toxicity Criteria should be evaluated using the following guidelines: D...",
      "contentLength": 718,
      "originalLine": "11.1.4  to the investigational product."
    },
    {
      "index": 67,
      "title": "Adverse Event Reporting Period",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "11.2",
      "contentPreview": "Only those AEs that occur following randomization should be recorded on the Adverse Event CRF. All genitourinary AEs will be recorded for the patient’s entire participation in the study. All other adverse events will be recorded for the first 6 months following randomization. All SAEs will be record...",
      "contentLength": 355,
      "originalLine": "11.2 Adverse Event Reporting Period"
    },
    {
      "index": 68,
      "title": "Recording Adverse Events",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "11.3",
      "contentPreview": "Adverse events should only be recorded by an inves tigator or by a health -care provider qualified by training and experience. Patients should be asked in an open-ended manner about the occurrence of AEs. All AEs, regardless of whether or not ascribed to the investigational product, should be record...",
      "contentLength": 968,
      "originalLine": "11.3 Recording Adverse Events"
    },
    {
      "index": 69,
      "title": "Reporting Serious Adverse Events",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "11.4",
      "contentPreview": "11.4.1 The Investigator must notify the Sponsor of any event that meets one of the criteria for an SAE within one working day of learning of the event. This notification should be made to: Reporting Serious Adverse Events to the Sponsor Monica Rossi, MD Director, Clinical Research Spectrum Pharmaceu...",
      "contentLength": 1036,
      "originalLine": "11.4 Reporting Serious Adverse Events"
    },
    {
      "index": 70,
      "title": "STATISTICAL DESIGN AND ANALYSIS",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "12",
      "contentPreview": "This section contains an overview of the statistical design and analysis plan for this study. A detailed description of the statistical design and analyses is contained in the Statistical Analysis Plan....",
      "contentLength": 202,
      "originalLine": "12. STATISTICAL DESIGN AND ANALYSIS"
    },
    {
      "index": 71,
      "title": "General Considerations",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "12.1",
      "contentPreview": "To evaluate the anti -tumor effect of EOquin the efficacy analysi s will compare the proportion of patients that recur on or before year 2 for patients randomized to the TUR- BT plus EOquin group and for patients who are randomized to the TUR-BT plus placebo group. To evaluate the safety profile o...",
      "contentLength": 761,
      "originalLine": "12.1 General Considerations"
    },
    {
      "index": 72,
      "title": "Sample Size",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "12.2",
      "contentPreview": "The sample size was determined using the software nQuery Advisor 6.01 (Statisti cal Solutions Ltd., Cork, Ireland). This study has 1:1 randomization (TUR-BT plus EOquin vs. TUR- BT plus placebo). All patients will be assigned to one of the two treatment arms. Based on a 2 -sided test at the 5% sign...",
      "contentLength": 1316,
      "originalLine": "12.2 Sample Size"
    },
    {
      "index": 73,
      "title": "Analysis of Efficacy Endpoi nts",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "12.3",
      "contentPreview": "12.3.1 The primary efficacy analyses will be conducted on all Ta G1 -G2 patients. The primary efficacy parameter is recurrence rate at year 2. The recurrence rate is defined as the proportion of patients with histologically confirmed recurrence of the bladder tumor at any time after randomization an...",
      "contentLength": 1846,
      "originalLine": "12.3 Analysis of Efficacy Endpoi nts"
    },
    {
      "index": 74,
      "title": "Analysis Methods",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "12.4",
      "contentPreview": "For all binomial variables (i.e., recurrence rate, progression rate) the variables will be reported by calculating the proportion of patients with endpoints and the treatment difference will be analyzed using the Mantel -Haenszel Chi -Square. For all time -to-event variables (i.e., time to recurrenc...",
      "contentLength": 1024,
      "originalLine": "12.4 Analysis Methods"
    },
    {
      "index": 75,
      "title": "Analysis of Safety Endpoints",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "12.5",
      "contentPreview": "Safety analysis will include all patients randomized to the TUR -BT plus placebo group and all patients randomized to the TUR-BT plus EOquin group who have receive d at least one dose of EOquin and have had one safety assessment (see section 12.1) . Patients who have been randomized to the TUR-BT ...",
      "contentLength": 1729,
      "originalLine": "12.5 Analysis of Safety Endpoints"
    },
    {
      "index": 76,
      "title": "ETHICAL AND REGULATORY CONSIDERATIONS",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "13",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "13. ETHICAL AND REGULATORY CONSIDERATIONS"
    },
    {
      "index": 77,
      "title": "Protocol and Regulatory Compliance",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "13.1",
      "contentPreview": "The Investigator must conduct the study according to this protocol. The study must be conducted by all Investigators in compliance with Good Clinical Practices (GCP) as defi ned in the U.S. FDA Code of Federal Regulations 21 CFR 312 (Investigational New Drug Application), 21 CFR 50 (Protection of Hu...",
      "contentLength": 473,
      "originalLine": "13.1 Protocol and Regulatory Compliance"
    },
    {
      "index": 78,
      "title": "Protocol Amendments",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "13.2",
      "contentPreview": "Any changes to this protocol will be initiated by the Sponsor as a protocol amendment. The Investigator must submit the amendment to the IRB/IEC, with a revised Informed Consent Document if applicable. The Investigator must receive written approval from the IRB/IEC before the amendment may take effe...",
      "contentLength": 303,
      "originalLine": "13.2 Protocol Amendments"
    },
    {
      "index": 79,
      "title": "Regulatory Binder",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "13.3",
      "contentPreview": "To be in compliance with GCPs, the Investigator must maintain accurate, complete, and organized documentation supporting the conduct of the study. This documentation includes, but is not limited to, the following: study personnel’s qualifications and training, IRB/IEC approvals and communications, c...",
      "contentLength": 563,
      "originalLine": "13.3 Regulatory Binder"
    },
    {
      "index": 80,
      "title": "Informed Consent",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "13.4",
      "contentPreview": "Prior to the performance of any protocol- specific proc edures, informed consent must be obtained and documented by the use of a written Informed Consent Document approved by the Sponsor and the IRB/IEC. The Informed Consent Document must be signed and dated by the patient or by the patient’s legall...",
      "contentLength": 1830,
      "originalLine": "13.4 Informed Consent"
    },
    {
      "index": 81,
      "title": "Institutiona l Review Boards and Independent Ethics Committees",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "13.5",
      "contentPreview": "The protocol, Informed Consent Document, patient recruitment procedures (e.g., advertisements), information about payments and compensation available to patients, and any amendments must be approved by a properly constituted IRB or IEC in compliance with current regulations of the U.S. FDA, ICH guid...",
      "contentLength": 861,
      "originalLine": "13.5 Institutiona l Review Boards and Independent Ethics Committees"
    },
    {
      "index": 82,
      "title": "IRB/IEC Communications",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "13.6",
      "contentPreview": "The Investigator must make timely and accurate reports to the IRB/IEC on the progress of the study, at intervals not exceeding one year, as well as satisfying any other local IRB/IEC regulations regarding reporting, including reporting on safety aspects of the study (e.g., SAEs, safety letters). The...",
      "contentLength": 916,
      "originalLine": "13.6 IRB/IEC Communications"
    },
    {
      "index": 83,
      "title": "Curriculum Vitae and Medical Licenses",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "13.7",
      "contentPreview": "The Principal Investigator is responsible for ensuring that the study is being conducted by qualified personnel. Documentation of these qualifications must be maintained within the Regulatory Binder, and includes the following: Curriculum Vitae (CV): CVs for the Principal Investigator and all Subinv...",
      "contentLength": 785,
      "originalLine": "13.7 Curriculum Vitae and Medical Licenses"
    },
    {
      "index": 84,
      "title": "Patient Confidentiality",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "13.8",
      "contentPreview": "The Investigator must ensure that the patient’s confidentiality is maintained. Patient medical information obtained for the purposes of this study is confidential, and disclosure to third parties, other than those noted below, is prohibited. Patients should not be identified by name, social security...",
      "contentLength": 1331,
      "originalLine": "13.8 Patient Confidentiality"
    },
    {
      "index": 85,
      "title": "Financial Disclosure",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "13.9",
      "contentPreview": "Documentation of each Investigator’s proprietary or financial interest in Spectrum Pharmaceuticals, Inc. is required by the U.S. Code of Federal Regulations (21 CFR 54). A financial disclosure form provided by the Sponsor must be completed, signed, and dated by the Principal Investigator and each Su...",
      "contentLength": 1138,
      "originalLine": "13.9 Financial Disclosure"
    },
    {
      "index": 86,
      "title": "QUALITY ASSURANCE",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "14",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "14. QUALITY ASSURANCE"
    },
    {
      "index": 87,
      "title": "Routine Clinical Site Monitoring",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "14.1",
      "contentPreview": "Spectrum Pharmaceuticals CRAs or representatives will make a pre- study site visit (if deemed necessary) to determine the qualifications of the Investigator, inspect the clinical facilities, and fully inform the Investigator of his/her responsibilities and the procedures for assuring adequate and co...",
      "contentLength": 1109,
      "originalLine": "14.1 Routine Clinical Site Monitoring"
    },
    {
      "index": 88,
      "title": "Site Audits",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "14.2",
      "contentPreview": "The Investigator must permit inspection of the study files (e.g., source documentation such as clinic notes, nurses’ notes, radiological and laboratory records, CRFs, Regulatory Binder) by a Sponsor representative and by authorized representatives of the U.S. FDA or other applicable regulatory agenc...",
      "contentLength": 443,
      "originalLine": "14.2 Site Audits"
    },
    {
      "index": 89,
      "title": "DATA MANAGEMENT AND RECORDKEEPING",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "15",
      "contentPreview": "No content",
      "contentLength": 0,
      "originalLine": "15. DATA MANAGEMENT AND RECORDKEEPING"
    },
    {
      "index": 90,
      "title": "CRF Completion and Transmittal",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "15.1",
      "contentPreview": "Spectrum Pharmaceuticals w ill supply a protocol- specific set of CRFs for each patient. CRFs should be completed in a timely manner and must be available for review during routine monitoring visits. All CRFs should be completed in black ink and in a legible manner. All references to specific patien...",
      "contentLength": 1183,
      "originalLine": "15.1 CRF Completion and Transmittal"
    },
    {
      "index": 91,
      "title": "Data Corrections",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "15.2",
      "contentPreview": "All corrections to source documents or to entries in the CRF must be initialed and dated by the individual making the correction. Corrections must be made by drawing a single line through the incorrect entry and recording the correct entry nearby. Incorrect entries should not be obliterated; the ori...",
      "contentLength": 414,
      "originalLine": "15.2  Data Corrections"
    },
    {
      "index": 92,
      "title": "Record Retention",
      "level": 2,
      "source": "pattern",
      "patternType": "numbered-sub",
      "number": "15.3",
      "contentPreview": "Records that individually or collectively permit the evaluation of the conduct of the study and the quality of the data produced with this study must be maintained for review by the Sponsor’s representatives and by U.S. and non-U.S. regulatory authorities. The Investigator must retain these records ...",
      "contentLength": 1261,
      "originalLine": "15.3 Record Retention"
    },
    {
      "index": 93,
      "title": "COMPENSATION, INSURANCE AND INDEMNITY",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "16",
      "contentPreview": "Information regarding compensation, insurance and indemnity will be provided to the Investigator in the Clinical Trial Agreement. 17. USE OR PUBLICATION OF STUDY- RELATED INFORMATION All information obtained as a result of this study should be regarded as confidential. Information regarding use or p...",
      "contentLength": 409,
      "originalLine": "16. COMPENSATION, INSURANCE AND INDEMNITY"
    },
    {
      "index": 94,
      "title": "INVESTIGATOR AGREEMENT",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "18",
      "contentPreview": "A Multicenter, Randomized, Double -Blind, Placebo -Controlled, Phase 3 Trial of Single -Dose Intravesical EOquin as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer I understand that all information concern...",
      "contentLength": 965,
      "originalLine": "18. INVESTIGATOR AGREEMENT"
    },
    {
      "index": 95,
      "title": "FUNCTIONAL BLADDER CAPACITY",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "19",
      "contentPreview": "Approximately 10-15 US sites will be selected to assess functional bladder capacity. Patients randomized at these sites will comprise the 150 patient cohort in whom functional bladder capacity will be assessed. Procedure for Functional Bladder Capacity Assessment : Initial Assessment: Prior to rando...",
      "contentLength": 1032,
      "originalLine": "19. FUNCTIONAL BLADDER CAPACITY"
    },
    {
      "index": 96,
      "title": "SCHEUDLE OF EVENTS",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "20",
      "contentPreview": "Wk2 Month4 0 3 3 6 9 12 15 18 21 24 VISIT NUMBER Procedure Scr 1 2 Add Rx3 3 4 5 6 7 8 9 10 Obtain informed consent X Medical history X Vital signs X X X X X X X X X X X Weight X Physical examination X CBC/chemistry panel X X5 X X Urine analysis6 X X5 X X X X X X X X X Pregnancy Test1 X Urine cytolo...",
      "contentLength": 340,
      "originalLine": "20. SCHEUDLE OF EVENTS"
    },
    {
      "index": 97,
      "title": "X       X    X",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "7",
      "contentPreview": "TUR -BT X Randomization X Instill study drug X Brief physical exam X X X X X X X X X Cystoscopy X X X X X X X X Adverse Events X X X X GU GU GU GU GU GU Con Meds X X X X GU GU GU GU GU GU...",
      "contentLength": 187,
      "originalLine": "7 X       X    X"
    },
    {
      "index": 98,
      "title": "All females of childbearing potential",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "1",
      "contentPreview": "2. Window is ±10 days 3. Additional treatment for higher grade/stage patients only 4. Window is ±10 days for Ta, G1-G2 patients: Window is ±20 days for higher grade and stage patients 5 May be performed up to 24 hours prior to surgery...",
      "contentLength": 234,
      "originalLine": "1 All females of childbearing potential"
    },
    {
      "index": 99,
      "title": "Urine dipsticks will be provid ed by the sponsor",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "6",
      "contentPreview": "7 performed at selected US sites only, prior to randomization includes voided volume+postvoid bladder scan+3 day voiding diary...",
      "contentLength": 126,
      "originalLine": "6 Urine dipsticks will be provid ed by the sponsor"
    },
    {
      "index": 100,
      "title": "RELEVANT LITERATURE REFERENCES",
      "level": 1,
      "source": "pattern",
      "patternType": "numbered-main",
      "number": "21",
      "contentPreview": "1. Network, N.C.C., Clinical Practice Guidelines in Oncol ogy. Bladder Cancer Version 1. 2006. 2. DeVita, V., et al., Cancer. Principles and Practice of Oncology. 7th ed. 2005: Lippincott Williams and Wilkins. 1168-1173. 3. Botteman, M., et al., The health economics of bladder cancer: a comprehensiv...",
      "contentLength": 1042,
      "originalLine": "21.  RELEVANT LITERATURE REFERENCES"
    }
  ]
}